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Abstract
Primary tumor location is an established prognostic factor in patients with (meta-
static) colon cancer. Colon tumors can be divided into left-sided and right-sided tu-
mors. The aim of this study was to determine the impact of primary tumor location on 
treatment and overall survival (OS) in patients with peritoneal metastases (PM) from 
colon cancer. This study is a retrospective, population-based cohort study. Records 
of patients diagnosed with colon cancer and synchronous PM, from 1995 through 
2016, were retrieved from the Netherlands Cancer Registry (NCR). Data on diagno-
sis, staging, and treatment were extracted from the medical records by specifically 
trained NCR personnel. Information on survival status was updated annually using 
a computerized link with the national civil registry. In total, 7930 patients were in-
cluded in this study; 4555 (57.4%) had a right-sided and 3375 (42.6%) had a left-sided 
primary tumor. In multivariable analysis right-sided primary tumor was associated 
with worse OS (HR: 1.11, 95% CI 1.03-1.19, P = .007). Of all patients diagnosed 
with PM, 564 (7.1%) underwent cytoreductive surgery and hyperthermic intraperi-
toneal chemotherapy (CRS-HIPEC). Patients with left-sided primary tumors were 
more often candidates for CRS-HIPEC (6.5% vs. 8.0%, P =  .008). OS of patients 
with right- and left-sided tumors who underwent CRS-HIPEC did not significantly 
differ. In conclusion, primary right-sided colon cancer was an independent prognos-
tic factor for decreased OS in patients diagnosed with synchronous PM. In patients 
treated with CRS-HIPEC location of the primary tumor did not influence survival.
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1 |  INTRODUCTION
Approximately 5% of all patients with primary colon can-
cer, present with synchronous peritoneal metastases (PM).1 
Cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy (CRS-HIPEC) has led to an increased overall 
survival (OS) of patients with PM from colon cancer over 
the last two decades, but also has considerable postoperative 
morbidity and mortality rates.2-10
Examples of risk factors for patients with PM associ-
ated with impaired survival include the extent of perito-
neal disease, extraperitoneal metastases, advanced primary 
tumor stage, nodal metastases, poor tumor differentiation, 
and poor performance status.10-12 Several studies have 
shown that primary tumor location also is a prognostic fac-
tor in patients with (metastatic) colon cancer.13-16 Colon 
tumors can be divided into left-sided and right-sided tu-
mors. Right- and left-sided primary tumors differ in em-
bryological origin (mid-gut vs hind-gut), bacterial flora 
and tumor biology (ie, mutational status and microsatellite 
instability (MSI)).17-19 In patients with metastatic colon 
cancer it is known that patients with right-sided tumors 
have worse tumor response rates to treatment with sys-
temic chemotherapy, in both an adjuvant and palliative set-
ting, and impaired survival outcomes. Other studies have 
shown that in patients who underwent resection for liver 
metastases, right-sided primary tumor was independently 
associated with impaired outcomes as well.20-24 However, 
little is known about the role of primary tumor location in 
patients with PM, and patients with PM undergoing CRS-
HIPEC.25,26 The aim of this study was to assess the impact 
of the primary tumor location in all patients with PM of 
colon cancer on a population-based level.
2 |  METHODS
2.1 | Collection of data
This was a retrospective, population-based cohort study in 
the Netherlands, a high-income Western-European country 
with currently over 17 million inhabitants. Data on patients 
with colon cancer diagnosed with synchronous PM from 
1995 through 2016, were retrieved from the Netherlands 
Cancer Register (NCR), after formal approval by the NCR 
Monitoring Committee. The NCR collects data on all patients 
(no age restrictions) diagnosed with cancer in the Netherlands 
based on notification of newly diagnosed malignancies by 
the national automated pathological archive and on hospital 
discharge diagnoses. Before 2008, data regarding the loca-
tion of metastases were collected for several regions in the 
Netherlands, since 2008 these data are collected on a pop-
ulation-based level. Information on baseline characteristics, 
staging, treatment, and survival was extracted routinely from 
the medical records by trained NCR personnel. Information 
on survival status is updated annually using a computerized 
link with the Dutch population register. For the present anal-
ysis, survival information was updated to 31 January 2018. 
The NCR does not collect data on disease-free survival.
2.2 | Patient selection
All patients diagnosed with colon cancer and synchronous 
PM between 1995 and 2016 were eligible for inclusion in 
this study. As all data were anonymized, no formal approval 
of a medical ethic committee was required under Dutch 
law. Right-sided primary tumors were defined as those of 
the cecum, ascending colon, hepatic flexure, and transverse 
colon. Left-sided tumors were defined as those of the splenic 
flexure, descending colon, sigmoid, or rectosigmoid. Patients 
with an unknown location of the primary tumor site and a 
primary appendiceal- or rectum tumor were excluded from 
this study.
2.3 | Definition and outcome parameters
Treatment approach was divided in treatment with curative 
intent (patients that underwent CRS-HIPEC) or treatment 
with palliative intent (systemic chemotherapy, palliative sur-
gery or best supportive care). All CRS-HIPEC procedures 
were performed according to the standardized Dutch CRS-
HIPEC protocol.7,27 Main outcome of this study was overall 
survival (OS). OS was calculated from the date of diagnosis 
until death or last follow-up. OS after CRS-HIPEC was cal-
culated from the date of surgery until death or last follow-up.
2.4 | Statistical analysis
Continuous variables were presented as median with inter-
quartile range (IQR). Categorical variables were presented as 
absolute numbers and percentages. Baseline characteristics 
were compared using the chi-squared test (for proportions) 
and Mann-Whitney U test (for continuous data). The Kaplan-
Meier method was used for survival analysis and comparisons 
between groups were made using log rank test. Patients were 
censored when alive at last follow-up date. Univariable and 
multivariable Cox proportional-hazards models were con-
structed to identify prognostic factors and hazard ratios (HR) 
and 95% confidence intervals (CI) for these factors were cal-
culated. Variables with a P-value < .05 or clinically relevant 
variables were included in the multivariable analysis. Two-
sided P-values < .05 were considered statistically significant. 
Statistical analyses were performed using Statistical Package 
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for Social Sciences (SPSS), Version 24.0.0 for Windows 
(IBM Corporation).
3 |  RESULTS
3.1 | Patient characteristics
3.1.1 | All patients diagnosed with 
peritoneal metastases
A total of 9759 patients were diagnosed with synchronous 
PM during the inclusion period. A total of 1839 patients 
(18.7%) were excluded because of unknown primary tumor 
site (n = 529, 5.4%), primary appendiceal tumor (n = 377, 
3.9%), or primary rectal cancer (n = 923, 9.5%). Therefore, 
7930 patients remained in the study for analysis. Baseline 
characteristics of the right- and left-sided tumor group are 
described in Table 1.
Patients with PM from right-sided primary tumors were 
older and more frequently females when compared to the 
left-sided tumor group. The right-sided tumor group also 
had more node positives and poor tumor differentiation was 
more common. In the left-sided tumor group extraperitoneal 
metastases were more frequent. Patients with PM from left-
sided tumors underwent CRS-HIPEC more frequently (all 
factors P < .01).
3.1.2 | Patients treated with CRS-HIPEC
Of all 7930 patients included in this study, 564 patients 
(7.1%) were treated CRS-HIPEC (Table 2). Female sex was 
more common in the right-sided tumor group. No other sig-
nificant differences were observed at baseline.
3.1.3 | Patients receiving 
palliative treatment
Most patients (92.9%) were treated with palliative intent. 
Table S1 includes baseline characteristics of these patients.
3.2 | Overall survival
3.2.1 | Overall survival of all patients 
diagnosed with peritoneal metastases
Median follow-up of all patients was 7.5 months [IQR 2.2-
17.6]. Of the 7959 patients included, 7439 (93.8%) died 
during the course of the study. The survival curve of these pa-
tients is shown in Figure 1A. Median OS of all patients diag-
nosed with synchronous PM was 7.5 months [IQR 2.2-18.2]. 
Median OS of right-sided tumors was worse as compared to 
the left-sided tumors (OS 7.0 months, IQR 2.1-16.7 vs OS 
8.6 months, IQR 2.4-20.4, P < .001).
After correction for possible confounders, multivariable 
analysis showed that a right-sided primary tumor was an in-
dependent prognostic factor for impaired survival (HR 1.11, 
95% CI 1.03-1.19, P = .007). Other prognostic factors asso-
ciated with worse survival outcomes were age at diagnosis, 
advanced tumor stage of the primary tumor, nodal metasta-
sis, existence of extraperitoneal metastasis, and poor tumor 
differentiation. Patients diagnosed within or after 2010, pa-
tients that received chemotherapy and patients that under-
went CRS-HIPEC had significant better outcomes (all factors 
P < .01). All results of univariable and multivariable analysis 
are shown in Table 3.
3.2.2 | Overall survival of patients treated 
with CRS-HIPEC
Median follow up after CRS-HIPEC was CRS-HIPEC was 
23.7 months [13.6-39.6]. At last follow up 197 (34.9%) of the 
patients that underwent CRS-HIPEC were still alive. OS of 
patients who underwent CRS-HIPEC was 33.0 months [IQR 
15.5-59.3]. There was no difference in OS between patients 
with right- or left-sided primary tumors who underwent CRS-
HIPEC (OS 30.3 months [IQR 15.2-58.1] vs OS 34.6 months 
[IQR 16.3-60.4], P = .301). Figure 1B shows the OS of all 
patients that were treated with CRS-HIPEC.
The results of univariable and multivariable analysis in 
patients treated with CRS-HIPEC are shown in Table 4. In 
patients who underwent CRS-HIPEC right-sided primary 
tumor was not independently associated with impaired sur-
vival. Factors associated that were associated with an im-
paired OS after CRS-HIPEC were poor tumor differentiation 
and nodal metastasis. Perioperative chemotherapy was as-
sociated with improved OS after CRS-HIPEC (all factors 
P < .01).
3.2.3 | Overall survival of patients receiving 
palliative treatment
Figures S1A-C show the survival curves of patients treated 
with palliative intent. In supplementary Table 2, the univari-
able an multivariable analysis of patients treated in a pallia-
tive setting can be found.
4 |  DISCUSSION
This current study showed that patients with synchronous 
PM from right-sided colon cancer had a worse prognosis as 
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Median [IQR]/N (%) P value
Age at diagnosis, years 70 [62-78] 69 [60-77] <.001
Sex <.001
Male 2102 (46.1) 1833 (54.3)
Female 2453 (53.9) 1542 (45.7)
Year of diagnosis .035
1995-1999 410 (55.9) 323 (44.1)
2000-2004 530 (53.9) 453 (46.1)
2005-2009 1293 (57.1) 970 (42.9)
≥2010 (2016) 2322 (58.8) 1629 (41.2)
Location primary N/A
Cecum 2161 (47.4)
Ascending colon 1186 (26.0)
Hepatic flexure 487 (10.7)
Transverse colon 721 (15.8)
Splenic flexure 377 (11.2)
Descending colon 353 (10.5)
Sigmoid colon 2301(68.2)
Recto sigmoid 344 (10.2)
pT-stage primary .225
T1-2 31 (0.7) 30 (0.9)
T3-4 2364 (51.9) 1675 (49.6)
Unknown 2160 (47.4) 1670 (49.5)
pN-stage primary <.001
N0 268 (5.9) 261 (7.7)
N+ 2039 (44.8) 1358 (40.2)
Unknown 2248 (49.4) 1756 (52.0)
Extraperitoneal metastasis <.001
Yes 2130 (46.8) 1737 (51.5)
No 2425 (53.2) 1638 (48.5)
Mucinous histology .894
Yes 923 (20.3) 688 (20.4)
No 3632 (79.7) 2687 (79.6)
Differentiation <.001
Well 112 (2.5) 106 (3.1)
Moderate 1448 (31.8) 1262 (37.4)
Poor 1276 (30.0) 730 (21.6)
Unknown 1719(37.7) 1277(37.8)
CTxb .082
Yes 2028 (44.5) 1569 (46.5)
No 2527 (55.5) 1806 (53.5)
CRS-HIPEC .008
Yes 294 (6.5) 270 (8.0)
No 4255 (93.4) 3103 (91.9)
Unknown 6 (0.1) 2 (0.1)
aCTx chemotherapy, CRS-HIPEC cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 
bCTx either administered in the palliative setting or in neoadjuvant or adjuvant setting or both. 










Age at diagnosis 62 [54-67] 61 [55-68] .880
Sex
Male 123 (41.8) 146 (54.1) .004
Female 171 (58.2) 124 (45.9)
Year of diagnosis
1995-2009 48 (44.9) 59 (55.1) .095
2010-2016 246 (53.8) 211 (46.2)
Location primary N/A
Cecum 155 (52.7) —
Ascending colon 68 (23.1) —
Hepatic flexure 18 (6.1) —
Transverse colon 53 (18) —
Splenic flexure — 22 (8.1)
Descending colon — 27 (10.0)
Sigmoid colon — 205 (75.9)
Recto sigmoid — 16 (5.9)
pT-stage primary .201
T1-2 6 (2.0) 2 (0.7)
T3-4 279 (94.9) 255 (94.4)
Unknown 9 (3.1) 13 (4.9)
pN-stage primary .746
N0 46 (15.6) 44 (16.3)
N+ 240 (81.6) 213 (78.9)
Unknown 8 (2.7) 13 (4.8)
Extraperitoneal 
metastasis
Yes 36 (12.2) 42 (15.6) .255
No 258 (87.8) 228 (84.4)
Mucinous histology .288
Yes 105 (35.7) 85 (31.5)
No 189 (64.3) 185 (68.5)
Differentiation .652
Well 8 (2.7) 6 (2.2)
Moderate 139 (47.3) 140 (51.9)
Poor 63 (21.4) 53 (19.6)
Unknown 84 (28.6) 71 (26.3)
Perioperative CTxb .736
Yes 201 (68.4) 181 (67.0)
No 93 (31.6) 89 (33.0)
Prior Surgery of 
primary
.059
Yes 153 (52.0) 117(43.4)
No 124 (42.2) 132 (48.9)
Unknown 17 (5.8) 21 (7.8)
aCTx chemotherapy, CRS-HIPEC cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 
bCTx either administered in the neoadjuvant setting or adjuvant setting or both. 
T A B L E  2  Baseline characteristics of 
patients treated with CRS-HIPEC
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compared to patients with PM from left-sided tumors. Patients 
in the latter group were more frequently candidates for CRS-
HIPEC. Other prognostic factors included age, advanced 
primary tumor stage (T3-T4), nodal metastases, poor tumor 
differentiation, extraperitoneal metastases, and whether or 
not the patient was treated with systemic chemotherapy and/
or CRS-HIPEC. In patients who underwent CRS-HIPEC the 
primary tumor location did not influence survival anymore. 
Prognostic factors for survival after CRS-HIPEC did include 
nodal metastases, poor tumor differentiation, and treatment 
with systemic perioperative chemotherapy, either adminis-
tered in the neoadjuvant or adjuvant setting or both.
Prior research has already shown that right- and left-sided 
colon tumors have different biological behavior and survival 
outcomes. This study confirms this for patients with syn-
chronous PM. However, in this study primary tumor location 
F I G U R E  1  Overall Survival curves of patients with synchronous peritoneal metastases from colon cancer. A, Overall survival of all patients 
after diagnosis. B, Overall survival of patients after undergoing CRS-HIPEC
Factor Univariable analysis Multivariable analysis
HR 95% CI P value HR 95% CI
P 
value
Age at diagnosis 
(cont.)
1.03 1.02-1.03 <.001 1.01 1.01-1.02 <.001
Female sex 1.05 1.00-1.09 .057
Year of 
incidence ≥ 2010
0.87 0.83-0.91 <.001 0.89 0.82-0.96 .002
Right-sided primary 1.12 1.07-1.18 <.001 1.11 1.03-1.19 .007
pT3-T4 (primary) 1.85 1.40-2.46 <.001 2.10 1.47-3.00 <.001
pN + CRC 1.67 1.51-1.84 <.001 1.83 1.63-2.05 <.001
Extraperitoneal 
metastasis
1.41 1.34-1.47 <.001 1.80 1.66-1.95 <.001
Poor differentiation 1.53 1.44-1.62 <.001 1.43 1.33-1.55 <.001
Mucinous histology 0.80 0.76-0.85 <.001 1.01 0.93-1.11 .771
Chemotherapy 0.46 0.44-0.48 <.001 0.48 0.44-0.52 <.001
CRS-HIPEC 0.29 0.26-0.32 <.001 0.57 0.50-0.65 <.001
Abbreviations: CI, confidence interval; CRC, colorectal cancer; CRS-HIPEC, cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy; HR, hazard ratio; pN+, lymph node positives.
T A B L E  3  Univariable and 
Multivariable Cox regression analysis 
for OS of all patients after diagnosis with 
peritoneal metastasis
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did not influence the results after CRS-HIPEC. This is re-
markable since most studies have shown that in patients who 
underwent resection for other colon cancer metastases (such 
as liver metastases), right-sided primary tumor was inde-
pendently associated with impaired outcomes.23,28,29 A pos-
sible explanation is that the prognosis of patients with PM is 
poor in general, and therefore no significant difference was 
found. Also, the lack of difference in survival outcomes could 
be due to the relative small sample size of the CRS-HIPEC 
group.
Two other cohort studies where recently published regard-
ing the impact of primary tumor location in patients treated 
with CRS and/or CRS-HIPEC.25,26 In contrast with the current 
results, a significant impaired DFS and OS was observed for 
patients with right-sided tumors after CRS and CRS-HIPEC. 
This difference could be due to the fact that both studies ex-
cluded all patients with a primary tumor in the transverse 
colon in their analysis. Others have shown a gradual change, 
for example, in microenvironment, from the ascending colon 
to the rectum.18,30,31 Excluding all primary tumors from the 
transverse colon could have resulted in an increased, and 
significant difference between left and right-sided tumors. 
When we excluded all patients with a primary tumor in the 
transverse colon from our own analysis the difference in OS 
between patients with right- or left-sided primary tumors 
who underwent CRS-HIPEC increased with 1.5 months, to a 
total difference of 5.8 months (OS 28.8 months [IQR 13.55-
56.7] vs OS 34.6 months [IQR 15.5-60.4], P = .149 (data not 
shown)). Another possible explanation for the dissimilarity in 
results, is referral bias. Both studies included only high-vol-
ume referral centers, while we performed a population-based 
study. It is published that patients treated in referral centers 
have different characteristics when compared with the gen-
eral population.32
The results of this study suggest that perioperative che-
motherapy results in better OS after CRS-HIPEC. Possible 
explanations include a true positive effect of perioperative 
chemotherapy on patients with synchronous PM, or selection 
bias. Patients who received treatment with (neo)adjuvant sys-
temic were probably in a better overall condition and did not 
show progression under neo adjuvant treatment. Patients who 
received adjuvant chemotherapy are less likely to have expe-
rienced very early progression postoperatively or a delayed 
postoperative course due to severe surgical complications. 
Therefore this is a selected group. Upfront CRS-HIPEC is 
currently standard of care for patients with resectable PM in 
the Netherlands. However, in other countries perioperative 
chemotherapy combined with CRS-HIPEC is common prac-
tice. The effect of neoadjuvant systemic therapy for patients 
with resectable PM is being studied in a national multicenter 
randomized controlled trial in the Netherlands (CAIRO6 
study). In this trial patients are randomized to either upfront 
CRS-HIPEC or CRS-HIPEC plus perioperative systemic 
chemotherapy. This study will provide the OS data to deter-
mine which treatment is superior.33
Unfortunately, the majority of patients (>90%) with PM 
from colon cancer are not eligible for treatment with cu-
rative intent. This study shows that patients with PM from 
Factor Univariable analysis Multivariable analysis
HR 95% CI P value HR 95% CI
P 
value
Age at surgery 
(cont.)
1.01 1.00-1.02 .149
Female sex 0.88 0.71-1.09 .240
Year of incidence 
(≥2010)
1.10 0.84-1.45 .488
Right-sided primary 1.12 0.90-1.39 .302 1.24 0.96-1.60 .098
pT3-T4 (primary) 6.00 0.84-42.77 .074




Poor differentiation 1.74 1.34-2.26 <.001 1.58 1.21-2.08 .001
Mucinous histology 0.83 0.66-1.04 .098
Peri-operative 
chemotherapy
0.71 0.57-0.90 .004 0.65 0.49-0.86 .003
Prior surgery of 
primary tumor
0.76 0.61-0.94 .013 0.82 0.63-1.06 .127
Abbreviations: CI, confidence interval; CRC, colorectal cancer; CRS-HIPEC, cytoreductive surgery and 
hyperthermic intraperitoneal chemotherapy; HR, hazard ratio; pN+, lymph node positives.
T A B L E  4  Univariable and 
Multivariable Cox regression analysis for 
OS of patients treated with CRS-HIPEC
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right-sided colon cancer who are treated in a palliative setting 
have a worse OS after diagnosis as compared to patients with 
PM from left-sided tumors. In patients treated with palliative 
chemotherapy right-sided primary tumor was associated with 
impaired survival. This suggests that treatment with che-
motherapy is less effective in patients with right-sided pri-
mary tumors, which is concordant with previously published 
studies which included mainly patients without PM.20,21,34 
Median OS of palliative patients not treated with chemother-
apy was dismal (<3 months). In these patients, there was no 
significant difference between left- and right-sided tumors.
The baseline characteristics of this study population are 
comparable with those previously reported on patients with 
metastatic colon cancer. Prior research also showed that right-
sided primary tumors are more frequently found in females, 
diagnosed at a more advanced stage and are more likely to be 
characterized by mucinous histology.13,15,22,35,36 Other prog-
nostic factors observed were in line with the literature as well.
Using data retrieved from the NCR has many advantages. 
These include the sample size, the population-based design 
and, as a consequence, the ability to report on all patients 
with synchronous PM, as opposed to many studies that focus 
on a specific treatments such as CRS-HIPEC. But, inherently 
to the design and the data source this study has limitations. 
The NCR only collected data on patients with synchronous 
PM of colon cancer. Therefore, no conclusions can be drawn 
for patients with metachronous PM. The NCR also did not 
collect data on the extent of peritoneal disease scored with the 
peritoneal cancer index (PCI) or on the completeness of cy-
toreduction during CRS-HIPEC, which are both well-known 
prognostic factors after CRS-HIPEC. Mutational status and 
microsatellite status of the tumor was not widely available. 
While prior research has shown that these are all prognos-
tic factors for patients with metastatic colon cancer, and 
right-sided tumors have been associated with more BRAF/
RAS mutations.34,37-41 Consequently, the results of this study 
should be interpreted with care.
In conclusion, this population-based study showed that pa-
tients with synchronous PM originating from right-sided colon 
cancer have an impaired OS as compared to left-sided primary 
tumors. However, after CRS-HIPEC there is no significant dif-
ference in the outcomes of right- and left-sided primary tumors.
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